Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 13/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441305 | 0.85 | HDAC1 (0.46) | FDPSESR1ESR2GGPS1 | |
| SCHEMBL11406548 | 0.83 | PTPN1 (0.46) | FDPSTSHRGGPS1 | |
| SCHEMBL2030830 | 0.82 | FDPS (0.47) | FDPSLMNACYP1A2CYP3A4TSHR | |
| SCHEMBL6769521 | 0.80 | FDPS (0.42) | FDPSSMPD1ESR1ESR2GGPS1 | |
| SCHEMBL11759783 | 0.80 | PTPN1 (0.46) | FDPSESR1ESR2GGPS1 | |
| SCHEMBL2035156 | 0.80 | FDPS (0.42) | FDPSLMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11411164 | 0.79 | GGPS1 (0.49) | FDPSSMPD1GGPS1 | |
| SCHEMBL11475619 | 0.78 | FDPS (0.47) | FDPSSMPD1GGPS1 | |
| SCHEMBL11418608 | 0.77 | GGPS1 (0.50) | FDPSSMPD1GGPS1 | |
| SCHEMBL11413454 | 0.77 | GGPS1 (0.50) | FDPSSMPD1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | FDPS 1145/4885CNR1 3979/4885CNR2 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.